Plasma Lipid Profiling Identifies Biomarkers of Cerebral Microvascular Disease

Ida Azizkhanian¹, Sunil A. Sheth², Anthony T. Iavarone³, Songmi Lee², Visesha Kakarla⁴ and Jason D. Hinman**

¹ New York Medical College School of Medicine, Valhalla, NY, United States, ² Department of Neurology, UT Health McGovern School of Medicine, Houston, TX, United States, ³ QB3/Chemistry Mass Spectrometry Facility, University of California, Berkeley, Berkeley, CA, United States, ⁴ Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States

Brain-specific sphingolipids (SLs) may serve as effective biomarkers of white matter hyperintensities (WMH). Here, we investigate the efficacy of SLs as a novel fluid-based biomarker to identify WMH reflective of chronic ischemia. Patients presenting to our stroke center for evaluation of acute neurological deficits were enrolled in the Advanced Serum Profiling in Recent Stroke (ASPIRE) study. From this cohort of 202 individuals, 58 patients who underwent an MRI and did not have a clinical stroke event were included in this study. Plasma samples were collected at the time of MRI, and targeted SL profiling was performed by HPLC/tandem mass spectrometry. T2 FLAIR imaging was evaluated for WMH and scored according to the Fazekas scoring (FS) method and manually quantified. Twenty two SLs were definitively identified, consisting of ceramide (Cer) and sphingomyelin (SM) species. Of these, two sphingolipids, SM 38:1 and Cer 34:1, significantly correlated with high FS (r = 0.287, p = 0.029, and r = 0.356, p = 0.006, respectively) and were used in subsequent analysis. SM 38:1 (OR 1.129, 95% CI 1.032, 1.236, p = 0.008) and Cer 34:1 (OR 1.118, 95% CI 1.031, 1.212, p = 0.007), accurately differentiated between FS 0–2 vs. 2.5–6 in regression analysis. A combined lipid score demonstrated fair discrimination in ROC analysis (AUC = 0.729, p = 0.003) and was cross-validated using leave-one-out analysis. Plasma levels of brain-specific SLs may serve as effective biomarkers of subacute white matter disease.

Keywords: sphingolipids, stroke, white matter (WM), biomarker, ceramide (CER), sphingomyelin (SM)

INTRODUCTION

White matter hyperintensities (WMH) detected on T2 weighted images are associated with white matter damage and can be identified in 11% of adults over 60 and in 94% of adults over 82 (1). While age is the most consistent risk factor for WMH; diabetes, smoking, and hypertension are also independent risk factors, suggesting that WMHs are pathological rather than a part of the normal aging process (2). A meta-analysis of 22 imaging studies evaluating WMH shows that these lesions are associated with increased risk of stroke (hazard ratio 3.3) and dementia (hazard ratio 1.9) (3). Increased WMH load is also associated with increased severity of cognitive dysfunction (4). WMH are associated with poor recovery after stroke and hemorrhagic transformation after thrombolysis (3, 5–9). Other evidence supports an association with gait disturbances and impaired balance,
putting those with significant WMH load at risk for falls and hospitalizations (2). Populations with limited access to healthcare and MRI studies may have underreported WMH and unrecognized cognitive impairment mandating alternative detection methods for WMH in these populations to promote screening, early intervention and appropriate management to prevent complications and hospitalizations.

Existing blood biomarkers for cerebral vascular disease are not specific to WMH and are not reliably detected in subclinical, or early stages of disease (10). While BNP and CRP are elevated in acute stroke and have shown modest ability to predict risk of future stroke, these biomarkers fail to reflect current extent of cerebral injury (11, 12). Non-specific inflammatory markers such as CRP, TNF, and IL-6, have not been shown to relate to WMH load (13). While some markers of endothelial damage, such as von Willebrand factor and intercellular adhesion molecule 1 are not associated with increasing WMH volume, others, including circulating vascular adhesion molecule-1, are (13, 14). Therefore, the role of different inflammatory pathways in the progression of WMH remains unclear. Serum neurofilament light chain (sNfL) has been recently shown to be a brain-specific biomarker for acute ischemic stroke (15, 16). While sNfL levels are reported to increase with acute ischemic damage and WMH, levels also increase in other neurological disorders including motor neuron disease (MND), multiple sclerosis (MS), and Alzheimer’s disease (AD) (17–20). Because AD, MND, and WMH are all more prevalent in the older patient population, sNfL can only be used as a non-specific biomarker for WMH.

Tissue pathology from regions of WMH reveals demyelination, axonal damage, and mild gliosis (21), arising from chronic microvascular dysfunction. Oligodendrocyte vacuolization around venules in perivascular spaces contributes to loss of myelination, axonal damage and white matter fiber disruption in regions of WMH. Both histological and diffusion tensor imaging evidence suggest that white matter changes extend into a penumbra surrounding the region of WMH detected by routine MRI (22–24). Therefore, MRI may underestimate extent of brain injury and can fail to detect early changes. Plasma biomarkers that reflect direct damage to white matter may serve a critical role in identifying early white matter injury.

We previously demonstrated that sphingolipids (SLs) are highly enriched in the brain and that plasma SLs are sensitive markers of acute ischemic cerebral injury. SLs, and in particular one subset of SLs known as sphingomyelins, are known to be key components of cerebral white matter, as major constituents of the cerebral myelin sheaths that contribute to membrane fluidity and structural integrity (25). In this study, we determine the ability of circulating SLs to serve as accurate biomarkers of WMH.

**SUBJECT/MATERIALS AND METHODS**

**Ethics Statement**

Research involving human subjects was approved by the Institutional Review Board of the University of California, Los Angeles (IRB # 14-001798) and was conducted in compliance with the Health Information Portability and Accountability Act. A board-certified Neurologist interviewed all patients to determine the capacity of each individual participant to provide informed consent. If in the opinion of the physician the patient suffered from a compromised ability to provide consent, a surrogate consent procedure was instituted whereby the next of kin or legally authorized representative was given the opportunity to consent on the patient’s behalf. Formal written consent was obtained for all participants prior to the collection of blood samples.

**Study Design**

This cohort study was prospectively designed to build from the results of our previous discovery-phase study, to validate findings on lipid biomarkers of acute ischemic stroke in a larger, real-world clinical cohort. Consecutive participants were patients presenting to the Ronald Reagan UCLA Emergency Department with symptoms concerning for stroke between December 2014 and June 2016 and who were offered the opportunity to participate in the study. Patients were included in this study if they had onset of stroke symptoms within 8 h of presentation (or within 2 h of presentation if symptoms were present upon awakening from sleep and the time of symptom onset was unknown); were >18 years of age and were able to offer informed consent or had a suitable surrogate individual who could consent on their behalf. The final clinical diagnosis was based on the results of a detailed evaluation of each patient by the Neurovascular Neurology service. Blood samples were collected by peripheral vein venipuncture into heparin-containing tubes. Samples were kept on ice and then centrifuged immediately at 13,000x g for 5 min at 4°C. The plasma was collected and aliquoted into freezer vials for storage at −80°C. Subjects with evidence of CNS infection, known CNS malignancy, or recent head trauma as a potential cause of neurologic symptoms were excluded. There were no other neurological conditions that met criteria for exclusion. In this pre-specified post hoc subset analysis, patients were included if they underwent MRI at the time of blood collection, and were not ultimately diagnosed as having an acute ischemic stroke or TIA. Descriptive statistics are presented on the cohort as a whole, and then for the purposes of model derivation to identify potential biomarkers of subacute cerebral microvascular disease, only stroke mimic cases were used and a leave-one-out validation was performed. Patients with stroke mimics had a range of pathologies including migraines, brain tumors, and syncope (Table 1).

**Sphingolipid Extraction**

Lipid extraction and detection were performed in an identical manner as previously reported (26). Briefly, 20 µL of plasma was placed in 13 × 100 mm screw-capped borosilicate glass test tubes with Teflon caps (Fisher Scientific Catalog Number 14-933A, New Jersey, USA). 0.5 mL of methanol followed by 0.25 mL of chloroform (Fisher Scientific, New Jersey, USA) and 10 µL of internal standards (Sph/Cer Mixture II, Catalog Number LM-6002, Avanti Polar Lipids, Alabaster, AL) were added. Samples were then sonicated in an ultrasonic bath until they appeared evenly dispersed and then incubated for 2 h at 48°C in a heating block. Tubes were then cooled to room temperature and 75 µL of
### Stroke mimic pathologies.

| Stroke mimic                  | Number (%) |
|-------------------------------|------------|
| Migraine                      | 12 (20.7)  |
| Seizure                       | 7 (12)     |
| Anxiety                       | 3 (5.2)    |
| Bell’s palsy                  | 2 (3.4)    |
| Dementia                      | 2 (3.4)    |
| Tumor                         | 2 (3.4)    |
| Hypertension                  | 4 (6.9)    |
| Acute coronary syndrome       | 2 (3.4)    |
| Syncope                       | 2 (3.4)    |
| Vestibular                    | 3 (5.2)    |
| Intoxication                  | 1 (1.7)    |
| Multiple sclerosis            | 1 (1.7)    |
| Other/unknown                 | 6 (10.3)   |

1M KOH was added. This mixture was sonicated briefly and then incubated for 30 min at 37°C. Samples were then cooled to room temperature and neutralized by addition of 16 μL of glacial acetic acid (Fisher Scientific, New Jersey, USA). pH was checked with test strips to verify near return to neutral pH 7.0. One milliliter of chloroform and 2 mL of water were added to each tube. The solution was mixed gently and centrifuged at 300 x g for 5 min to separate the phases. A Pasteur pipette was rinsed with chloroform and then used to remove the lower layer into another glass test tube, and the solvent was removed using vacuum centrifugation. The lipid residue was then re-dissolved in 75 μL methanol. The upper phase was re-extracted by adding 1 mL chloroform, mixing gently, and centrifuging as above. The lower layer was again transferred to another glass test tube using a Pasteur pipette that had been rinsed with chloroform, and the solvent was removed using vacuum centrifugation. The lipid residue was re-dissolved in 75 μL methanol. These two extracts were then pooled for a total of 150 μL, vortexed, and then centrifuged at 13,000 x g to clarify. The supernatant was then transferred to an autosampler vial (Catalog number 225180, Wheaton, New Jersey, USA). Vials were stored at −80°C until ready for LC-MS analysis.

### High Performance Liquid Chromatography-Mass Spectrometry

Chromatography-Mass Spectrometry

Sphingolipid Biomarkers for White Matter Disease

Chromatography-Mass Spectrometry

Sphingolipid Biomarkers for White Matter Disease

Sphingolipid Identification

Raw Thermo MS data files were converted into centroided data and into the mzXML format using the MS Convert tool in the ProteoWizard 3.0 package (27). Retention time correction and automated peak picking were then performed using XCMS online (28). Feature detection was performed using the centWave method at 2 parts per million (ppm) m/z deviation, minimum peak width of 20 s and maximum peak width of 80 s. A 20 s retention time deviation (bw) was used with a width of 0.01 s for overlapping m/z slices (mzwid). Peaks were annotated by searching for isotopes plus selected adducts (H+ and Na+) with an m/z absolute error of 0.015 and relative error of 5 ppm. Parameters were iteratively optimized by manual review of the selective peaks.

From the automatically selected peaks, target lipids were identified from the METLIN database with the annotation parameters described above (Scripps Research Institute, La Jolla, CA). Peaks were then filtered to only include SLs, and then
manually reviewed to ensure accuracy. Peaks that were felt to be inappropriately selected were excluded. Thus, the final list of included SLs consisted of automatically selected peaks that were manually curated.

**Imaging Analysis**

MRI was performed on either Siemens Avanto 1.5T or Siemens Trio 3T machines. Axial T2-weighted images were obtained continuously in 5-mm-thick sections with repetition time of 3,800 ms and time to echo of 116 ms. The field of view was 220 cm, and the matrix was 384 × 384. Axial FLAIR images were obtained continuously in 5-mm-thick sections with repetition time of 9,000 ms and time to echo of 89 ms. The field of view was 220 cm, and the matrix was 320 × 216. Axial diffusion-weighted images were obtained continuously in 5-mm-thick sections with repetition time of 5,600 ms and time to echo of 106 ms. The field of view was 255 cm, and the matrix was 192 × 192.

Two authors (I.A. and V.K.), who were blinded to clinical data, evaluated WMH on axial T2-weighted FLAIR images. The raters used the Fazekas subjective scoring method to assign a score from 0 to 3 in periventricular white matter (PVWM) and deep white matter (DWM) regions of the brain (29, 30). PVWM hyperintensities were scored 0, no hyperintensities; 1, caps or pencil thin lining; 2, smooth halo; 3, irregular periventricular signal extending into the DWM. The DWM was scored 0, no hyperintensities; 1, punctate foci; 2, beginning confluence; 3, large confluent areas. The total Fazekas score (FS) was obtained by summing the scores from periventricular and deep white matter regions. Interrater reliability as measured by quadratic weighted Cohen’s Kappa was excellent with $\kappa = 0.81$. The average of the scores assigned by the two authors was used in subsequent analysis. This endpoint was dichotomized to separate low WMH load (FS 0–2) from high WMH load (FS > 2). Other features of cerebral microvascular disease including microbleeds and perivascular spaces were also evaluated using axial gradient-echo sequences and axial T2-weighted sequences.

**White Matter Hyperintensity Segmentation**

WMH area was quantified using manual ROI segmentation in OsirIX Lite (Pixmeo SARL). WMH areas on individual T2-Weighted FLAIR MRI slices were carefully outlined using the wand tool and the total area of each lesion measured. Lesion areas were summed across slices, and classified as deep or periventricular. Deep and periventricular areas were calculated and then correlated with Fazekas scores and lipid species.

**Statistical Analysis**

Statistical analysis was performed using SPSS, Graphpad v 7.0, and Matlab v2018a software. Continuous variables with a normal distribution were described as mean ± SD, and non-normally distributed variables were described as median and interquartile range. For univariate analysis, categorical variables were compared by $\chi^2$ statistics. A Spearman’s correlation was used to measure the association between lipid species, FS, and measured WMH areas. Logistic regression analyses were performed to distinguish independent predictors of heavy white matter damage defined as previously described FS cut-offs. Leave-one-out cross-validation was performed in Matlab using defined code. Statistical significance was defined as $p < 0.05$.

**RESULTS**

**Subjects**

Demographic, clinical, radiographic, and plasma specimens were collected as part of the Advanced Serum Profiling in Recent (ASPIRE) Stroke study, a previously conducted UCLA IRB approved, single-center observational study that aimed to identify lipid biomarkers of acute stroke. Data for the ASPIRE trial were collected from all consenting patients over the age of 18 years old presenting to the emergency department (ED) between December 2014 and June 2015 with acute neurological symptoms within the prior 24 h. Subjects with evidence of CNS infection, known CNS malignancy, or recent head trauma as a potential cause of neurologic symptoms were excluded. Demographic data and neurodiagnostic studies are available for all enrolled patients.

To identify only those subjects with subacute white matter disease, the total study population was selectively reduced to exclude those presenting with imaging or clinically confirmed TIA/stroke and those without MRI imaging. Of the 202 patients enrolled in the ASPIRE Stroke study, 34 were excluded as they had not undergone MRI, and an additional 110 were excluded for being diagnosed ultimately with acute ischemic stroke or TIA (Figure 1). Among the 58 patients who presented with a stroke mimic syndrome and were included in this analysis, median age was 69.5 and 51.7% were female (Table 2). Higher FS was associated with advanced age (29 vs. 70% over 70 yo, FS 0–2 vs. 2.5–6, $p = 0.002$). While sex did not have an effect on FS in $\chi^2$ analysis ($p = 0.32$), age did ($p = 0.0041$). Fazekas positive status was given to 46.5% of the cohort for having FS > 2. Rates of other stigmata of cerebral microvascular disease in the stroke mimic cohort were low with only 5.5% having cerebral microbleeds and 17.8% having prominent perivascular spaces, the majority (>70%) of which also have FS > 2. Figure 2A demonstrates the distribution of Fazekas scores in the total ASPIRE cohort and the smaller stroke mimic cohort. Stroke mimics represented a variety of non-ischemic diagnoses ranging from migraine to syncope (Table 1).

**Sphingolipid Analysis**

Two species, SM 38:1 and Cer 34:1, significantly correlated with FS in a Spearman’s correlation model in both the overall ASPIRE cohort and the stroke mimic subgroup (Tables 3, 4). In multivariate logistic regression, SM 38:1 (OR 1.129, 95% CI 1.032, 1.236, $p = 0.008$) and Cer 34:1 (OR 1.118, 95% CI 1.031, 1.212, $p = 0.007$) also accurately differentiated between FS 0–2 vs. 2.5–6. When controlling for age, the two species were still independently predictive of WMH load: SM 38:1 (OR 1.125, 95% CI 1.010, 1.253, $p = 0.032$) and Cer 34:1 (OR 1.096, 95% CI, 1.002, 1.200, $p = 0.046$).

A composite lipid score (LS) was computed from the sum of these two lipid species and demonstrated fair discrimination in ROC analysis (Figures 2B,C). Leave-one-out validation
demonstrated a cross-validated $R^2$ of 12.54%, indicating reproducibility of the LS to predict WMHs resulting from cerebral microvascular disease. To further validate the specificity of the LS, we measured WMH area using FLAIR sequences within the stroke mimic cohort of ASPIRE. Of the 58 stroke mimic subjects, 44 subjects had scans allowing precise measurement of WMH. WMH burden correlated with FS ($r = 0.828$; $p = 4.1 \times 10^{-12}$) and significantly correlated with LS ($r = 0.459$; $p = 0.0017$). Figure 3 demonstrates the relationship between FS, LS, and WMH in this cohort. In linear regression analysis Cer 34:1 significantly associated with objective white matter measurements ($p = 0.003$), even when controlling for age as a covariate ($p = 0.003$). To evaluate other potential variables to include in the model, mean LS was compared in patients with and without hypertension, diabetes, history of statin use, sex, and low HDL levels. No significant differences in mean LS exist between these groups. Furthermore, these variables were not predictive of FS+ status in univariate binary logistic regression and were therefore excluded from the model.

To demonstrate the specificity of LS for clinically subacute WMH and not the presence of acute ischemic damage, SM 38:1, Cer 34:1, and LS levels were compared between the stroke mimic cohort ($n = 58$) and DWI positive stroke group ($n = 110$). While LS correlated with FS in acute stroke patients ($r = 0.440$, $p < 0.001$), overall SM 38:1 and LS levels were significantly lower in the acute stroke patients compared to stroke mimics (Table 5). There was a trend showing lower Cer 34:1 in the acute stroke patients as well, however, this difference did not reach statistical significance.

**DISCUSSION**

Biomarkers play an important role in timely detection and management of neurological diseases. The availability of a fluid-based biomarker for subacute ischemic white matter injury may aid in early detection of subacute ischemic brain damage and prevention of its progression to symptomatic stroke, global cognitive decline, and functional loss. Currently, no brain-specific biomarkers are in clinical use for the evaluation of WMH. WMH are a neuroimaging finding that may be indicative of ischemic brain damage and are often found incidentally yet convey considerable cerebrovascular risk. The high cost and relative inaccessibility of MRI studies for subacute neurological disease necessitate an alternative to neuroimaging for evaluation of chronic white matter disease.
A number of studies have suggested protein-based circulating biomarkers for ischemic white matter injury but these associations are highly variable among populations (31). Recent work suggests that serum detection of neurofilament light chain is transiently increased within 3 months of a recent small subcortical infarct, adding sensitivity to MRI confirmation of acute stroke but not necessarily reliable in the detection of subacute ischemic white matter injury (32). Here, we demonstrate that serum levels of two brain-specific lipid species, SM 38:1 and Cer 34:1, correlate with WMH load as measured by FS specifically in subjects with imaging confirmation of no recent brain ischemia. Summing the relative intensities of these lipids yields a LS that reliably distinguishes between low and high WMH load with a cut off of FS > 2. Quantitative assessments of WMH area further validated the role of LS as a blood-based biomarker for WMH in a clinically relevant study population.

An ideal biomarker for cerebrovascular disease is specific to the brain and can cross the blood-brain barrier (BBB) to be measured in serum or plasma from peripheral circulation. Leakage across the BBB is increasingly recognized as central to the pathogenesis of cerebral microvascular disease with evidence of fibrinogen and other plasma proteins leaking into the brain and white matter in individuals with cerebral microvascular disease (32, 33). While acute stroke can cause adequate disruption to the BBB for lipid species to cross over into systemic circulation, other conditions such as acute infection, migraines, or seizures may cause similar leaks and lead to false positive signals. However, subclinical ischemia is generally confined to the cerebral white matter and using a biomarker specific to myelin components may help tune specificity to white matter damage. Indeed, characterization of specific sphingolipid species indicates that those species increased in acute stroke (Cer 42:1 and SM 36:0) are independent and distinguishable from those relevant to WMs (Cer 34:1 and SM 38:1) (26).

Brain white matter is enriched for the lipid species investigated in this study. Composition of human brain white matter includes sphingomyelin and ceramide (34). Human myelin within white matter tracts comprises many different sphingomyelin species (26, 35). Both ceramide and sphingomyelin are key components of lipid rafts that play a key role in myelination and the maintenance of myelin (36, 37). CSF measurement of sphingomyelin species has been proposed as a biomarker for demyelination in peripheral neuropathies (38). Given the relative

![Image](57x113 to 539x262)

**TABLE 3 | Lipid screening analysis in stroke mimic cohort.**

| Lipids | M [IQR] | Spearman correlation |
|--------|---------|----------------------|
| SM 34:1 | 3889.5 [3148.2] | 3795 [2793.2] | 0.129 (p = 0.324) |
| SM 36:1 | 1347.7 [803.7] | 458.6 [918.2] | 0.182 (p = 0.0171) |
| SM 40:2 | 1012.1 [439.6] | 1015.5 [403.6] | 0.032 (p = 0.813) |
| SM 34:2 | 779.6 [809.2] | 793.1 [843.4] | 0.078 (p = 0.559) |
| SM 42:1 | 873.4 [409.1] | 896 [396] | 0.039 (p = 0.769) |
| SM 38:1 | 691.6 [402.0] | 702.7 [317.5] | 0.035 (p = 0.792) |
| SM 36:2 | 632.0 [316.9] | 667 [357.4] | 0.173 (p = 0.193) |
| SG 19:3 | 492.6 [307.2] | 452.3 [322.7] | 0.121 (p = 0.364) |
| SM 38:2 | 378.7 [174.6] | 406.9 [175.1] | 0.151 (p = 0.258) |
| SG 20:1 | 237.2 [189.5] | 225 [189.7] | 0.112 (p = 0.403) |
| SG 18:1 | 242.7 [183.6] | 237.3 [231.6] | 0.107 (p = 0.426) |
| SM 39:1 | 190.1 [134] | 181.8 [117.2] | 0.012 (p = 0.93) |
| SM 35:1 | 177.4 [91.4] | 193.9 [97.4] | 0.291 (p = 0.0277) |
| SM 40:3 | 143.4 [87.9] | 156.3 [65.8] | 0.194 (p = 0.145) |
| SM 37:1 | 95.4 [45.7] | 105.9 [53.2] | 0.215 (p = 0.105) |
| SM 43:2 | 86.0 [44] | 97.0 [46.4] | 0.270 (p = 0.04) |
| SM 38:1 | 75.6 [46.2] | 78.4 [38.8] | 0.169 (p = 0.204) |
| SM 39:2 | 42.8 [19] | 45.2 [22.7] | 0.186 (p = 0.163) |
| SM 36:3 | 35.1 [32.8] | 38.6 [37.0] | 0.167 (p = 0.209) |
| SM 38:3 | 23.7 [11.8] | 26.2 [14.6] | 0.235 (p = 0.076) |
| SM 38:1 | 16.9 [9.4] | 20.3 [12.3] | 0.287 (p = 0.029) |
| CR 34:1 | 13.3 [11.7] | 16.5 [14.5] | 0.356 (p = 0.006) |

**p**, level of significance; **r**, Spearman’s rho; **Fazekas +**, Fazekas score > 2; **M [IQR]**, median (interquartile range). **Correlation is significant at the 0.01 level (2-tailed).** **Correlation is significant at the 0.05 level (2-tailed).**

![Image](57x113 to 539x262)

**FIGURE 2 | Combined lipid score predicts WMH.** The distribution of Fazekas scoring for the total ASPIRE study cohort (black) and the stroke mimic cohort (gray) (A). Correlation of the combined Cer 34:1 + SM 38:1 lipid score with Fazekas scoring in the stroke mimic cohort (B). ROC curve for the combined lipid score as a predictor of WMH (C).
TABLE 4 | Lipid screening analysis in ASPIRE cohort.

| Lipids | Spearman correlation | Linear regression |
|--------|----------------------|------------------|
|        | r        | p     | β      | p     | 95% CI β |
| SM 34:1 | 0.032   | 0.728 |       |       |          |
| SM 36:1 | 0.061   | 0.513 |       |       |          |
| SM 40:2 | −0.091  | 0.323 |       |       |          |
| SM 34:2 | −0.016  | 0.860 |       |       |          |
| SM 42:1 | −0.090  | 0.330 |       |       |          |
| SM 38:1 | −0.094  | 0.310 |       |       |          |
| SM 36:2 | 0.028   | −0.143|       |       |          |
| SG 19:3 | −0.143  | 0.121 |       |       |          |
| SM 38:2 | −0.051  | 0.585 |       |       |          |
| SG 20:1 | −0.140  | 0.880 |       |       |          |
| SG 18:1 | −0.019  | 0.842 |       |       |          |
| SM 39:1 | −0.137  | 0.137 |       |       |          |
| SM 35:1 | 0.099   | 0.285 |       |       |          |
| SM 40:3 | 0.149   | 0.105 |       |       |          |
| SM 37:1 | 0.051   | 0.578 |       |       |          |
| SM 43:2 | 0.097   | 0.296 |       |       |          |
| SM 43:1 | −0.055  | 0.554 |       |       |          |
| SM 39:2 | 0.066   | 0.474 |       |       |          |
| SM 36:3 | 0.067   | 0.468 |       |       |          |
| SM 38:3 | 0.152   | 0.100 |       |       |          |
| SM 38:1 | 0.275   | 0.002** | 0.051 | 0.010 | (1.167, 2.472) |
| CR 34:1 | 0.375   | 0.001** | 0.062 | <0.001 | (0.032, 0.093) |

p, level of significance; r, Spearman’s rho; 95% CI, 95% confidence interval. **Correlation is significant at the 0.01 level (2-tailed).

FIGURE 3 | Relationship of combined LS with subjective and objective white matter hyperintensity measurements. For each stroke mimic cohort subject, combined lipid score values are plotted on the vertical z axis (arbitrary units) as a function of measured white matter hyperintensities (mm²) (left bottom axis) and Fazekas score (right bottom axis). Color scale corresponds to the summated log-normalized composite of each input variable (LS, WMH area, and FS).

TABLE 5 | Lipid biomarker levels in stroke mimic and tissue-defined stroke cohorts.

| Lipids     | Stroke mimic cohort | Tissue-defined stroke cohort |
|------------|---------------------|-----------------------------|
|            | n = 58              | n = 110                     |
| SM 38:1    | 15.5                | 12.8                        |
| Cer 34:1   | 11.68               | 9.67                        |
| LS         | 28.27               | 22.46                       |

Medians were compared with a one tailed Mann Whitney U-test. **, significance at the 0.01 level. LS, combined lipid score from sum of SM 38:1 and Cer 34:1; M, median; p, p-value.

abundance of myelin lipids to axonal protein components such as NF-L, leakage of these lipids into the periphery after injury may be a more sensitive indicator of subacute white matter injury. The design of this study enriches for chronic WMH but limits the ability to judge the specificity of LS in other demyelinating injuries.

The original ASPIRE Stroke study cohort of over 200 patients was initially reduced to only 58 to stringently select for those without acute stroke or TIA yet with evidence of WMH reflective of chronic ischemic damage. Despite excluding patients with acute stroke, this cohort is enriched for systemic disease and advanced age due to the original recruitment criteria of the ASPIRE study. Moreover, our approach of using routine clinical imaging as opposed to research grade MRI sequencing approaches that are often used in evaluation of white matter hyperintensity burden, necessarily reduces the accuracy of white matter hyperintensity load measurements but increases the potential applicability of the LS biomarker in clinical practice. Additional studies using precise volumetric measurements of WMH should be pursued to further validate this biomarker. Details on the microstructural integrity of white matter available using DTI images may also enhance the biological significance of sphingolipids through indirect measurement of myelin sheath breakdown.

A fluid-based biomarker for cerebral microvascular disease can serve as a valuable tool for detecting subacute brain ischemia. Exposing subclinical ischemia before its progression to symptomatic stroke or clinically apparent cognitive impairment can reduce disease burden in elderly and frail individuals already at elevated risk for acute stroke. Future studies will likely expand the role of this and other fluid-based biomarkers for WMH and provide a critical role for risk stratification in the study of stroke and vascular cognitive impairment and dementia.

DATA AVAILABILITY

The datasets generated for this study are available on request to the corresponding author.
AUTHOR CONTRIBUTIONS
IA, JH, and SS: conception and design of the study and drafting a significant portion of the manuscript or figures. IA, JH, SS, AI, SL, and VK: acquisition and analysis of data.

FUNDING
This study was supported by funding from the American Heart Association Grants #15CRP22900006 (SS) and Grant-in-Aid #16GRNT31080021 (JH) as well as the Medical Student Training in Aging Research Program sponsored by the National Institute on Aging (T35AG026736) and the Lillian R. Gleitsman Foundation. The QB3/Chemistry Mass Spectrometry Facility at UC Berkeley received support from the National Institutes of Health (#1S10OD020062-01).

ACKNOWLEDGMENTS
The authors are grateful to current and past members of the UCLA Student Stroke Force and UCLA Stroke Center Members who assisted in ASPIRE Trial enrollment and data collection.

REFERENCES
1. Ylikoski A, Erkinjuntti T, Raininko R, Sarna S, Sulkanen R, Turviva R. White matter hyperintensities on MRI in the neurologically nondiseased elderly: analysis of cohorts of consecutive subjects aged 55 to 85 years living at home. *Stroke.* (1995) 26:1171–7. doi: 10.1161/01.STR.26.7.1171
2. Wardlaw JM, Smith C, Dichgans M. Mechanisms underlying sporadic cerebral small vessel disease: insights from neuroimaging. *Lancet Neurol.* (2013) 12:483–97. doi: 10.1016/S1474-4422(13)70060-7
3. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BJM.* (2010) 341:c6366. doi: 10.1136/bmj.c6366
4. Wright CB, Dong C, Causson MC, DeRosa J, Kuen Cheng Y, Rundek T, et al. MRI markers predict cognitive decline assessed by telephone interview: the Northern Manhattan Study. *Alzheimer Dis Assoc. Disord.* (2017) 31:34–40. doi: 10.1097/WAD.0000000000000158
5. Jha B, Battey TW, Pham L, Lorenziano S, Furie KL, Sheth KN, et al. FLAIR hyperintensity correlates with MMP-9 level and hemorrhagic transformation in acute ischemic stroke. *Stroke.* (2014) 45:1040–5. doi: 10.1161/STROKEAHA.113.004627
6. Neumann-Haefelin T, Hoelig S, Berkefeld J, Fiehler J, Fialho J, Gass A, Rundeck Y, et al. MRI markers predict cognitive decline assessed by telephone interview: the Northern Manhattan Study. *Alzheimer Dis Assoc. Disord.* (2017) 31:34–40. doi: 10.1097/WAD.0000000000000158
7. Wharton SB, Simpson JE, Brayne C, Ince PG. Age-associated white matter lesions: the MRC cognitive function and ageing study. *Brain Pathol.* (2015) 25:35–43. doi: 10.1111/bpa.12219
8. IST-3 collaborative group. Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial. *Lancet Neurol.* (2015) 14:485–96. doi: 10.1016/S1474-4422(15)00012-5
9. Yamauchi H, Fukuda H, Oyanagi C. Significance of white matter high intensity lesions as a predictor of stroke from arteriolesclerosis. *J Neurol Neurosurg Psychiatry.* (2002) 72:576–82. doi: 10.1136/jnnp.72.5.576
10. Whiteley W, Tseng M-C, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. *Stroke.* (2008) 39:2902–9. doi: 10.1161/STROKEAHA.107.511261
11. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Law G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet.* (2010) 375:132–40. doi: 10.1016/S0140-6736(09)61777-7
12. Cushman M, Judd SE, Howard VJ, Kissela B, Gutierrés OM, Jenny NS, et al. N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. *Stroke.* (2014) 45:1646–50. doi: 10.1161/STROKEAHA.114.004712
13. Wiseman SL, Doubl FN, Chappell FM, Valdés-Hernández MC, Wang X, Runey A, et al. Plasma biomarkers of inflammation, endothelial function and hemostasis in cerebral small vessel disease. *Cerebrovasc Dis Basel Switz.* (2015) 40:157–64. doi: 10.1159/000348494
14. Tchalla AE, Wellenius GA, Sorond FA, Travin TG, Dantoine T, Lipsitz LA. Elevated circulating vascular cell Adhesion Molecule-1 (sVCAM-1) is associated with concurrent depressive symptoms and cerebral white matter Hyperintensities in older adults. *BMC Geriatr.* (2015) 15:62. doi: 10.1186/s12877-015-0063-7
15. De Marchis GM, Katam M, Barro C, Fladt J, Traenka C, Seiffge DJ, et al. Serum neurofilament light chain levels in patients with acute cerebrovascular events. *Eur J Neurol.* (2015) 22:562–8. doi: 10.1111/ejn.13554
16. Gattringer T, Pinter D, Enzinger C, Seifert-Held T, Knehúl M, Fandler S, et al. Serum neurofilament light is sensitive to active cerebral small vessel disease. *Neurology.* (2017) 89:2108. doi: 10.1212/WNL.0000000000004645
17. Gille B, De Schaepp dryer M, Goossens J, Deedene L, De Vocht J, Oldoni E, et al. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with amyotrophic lateral sclerosis. *Neuropathol Appl Neurobiol.* (2019) 45:291–304. doi: 10.1111/nan.12511
18. Goossens J, Bjerke M, Van Mossevelde S, Van den Bosche T, Goe man J, De Vil B, et al. Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. *Alzheimer Res Ther.* (2018) 10:31. doi: 10.1186/s13195-018-0364-0
19. Duering M, Konieczny MJ, Tiedt S, Baykara E, Tuldahm AR, Leijen EV, et al. Serum neurofilament light chain levels are related to small vessel disease burden. *Stroke.* (2018) 50:228–28. doi: 10.1093/str/awx158
20. Silfer N, Kuhle J, Muthuraman M, Barro C, Uphaus T, Groppa S, et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. *Mult Scler J.* (2019) 25:678–86. doi: 10.1177/1352458518765666
21. Wardlaw JM, Valdés Hernández MC, Muñoz-Maniega S. What are white matter hyperintensities made of? *J Am Heart Assoc.* (2015) 4:e001140. doi: 10.1161/JAHA.114.001140
22. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, et al. White matter lesions in an unselected cohort of the elderly. *Stroke.* (2006) 37:1391–8. doi: 10.1161/01.STR.0000221308.94473.14
23. Maillard P, Fletcher E, Harvey D, Carmichael O, Reed B, Mungas D, et al. White matter hyperintensity penumbra. *Stroke J Cereb Circ.* (2011) 42:1917–22. doi: 10.1161/STROKEAHA.110.609768
24. Maillard P, Fletcher E, Lockhart SN, Roach AE, Reed B, Mungas D, et al. White matter hyperintensities and their penumbra lie along a continuum of injury in the aging brain. *Stroke.* (2014) 45:1721–6. doi: 10.1161/STROKEAHA.113.004084
25. Gonzaález CE, Venkatraman VK, An Y, Landman BA, Davatzikos C, Ratnam Bandaru VV, et al. Peripheral sphingolipids are associated with variation in white matter microstructure in older adults. *Neurobiol Aging.* (2016) 43:153–63. doi: 10.1016/j.neurobiolaging.2016.04.008
26. Sheth SA, Lavorente AT, Liebeskind DS, Won SJ, Swanson RA, Targeted lipid profiling discovers plasma biomarkers of acute brain injury. *PLoS ONE.* (2015) 10(9):e0129735. doi: 10.1371/journal.pone.0129735
27. Chambers MC, Maclean B, Burke R, Amodio D, Ruderman DL, Neumann S, et al. A cross-platform toolkit for mass spectrometry and proteomics. *Nat Biotechnol.* (2012) 30:918–20. doi: 10.1038/nbt.2377
28. Gowda H, Ivanisevic J, Johnson CH, Kurczy ME, Benton HP, Rinehart D, et al. Interactive XCMS online: simplifying advanced metabolomic data processing and subsequent statistical analyses. *Anal Chem.* (2014) 86:6931–9. doi: 10.1021/ac500753c
29. Fazekas F, Chawluk J, Alavi A, Hurtig H, Zimmerman R. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. Am J Roentgenol. (1987) 149:351–6. doi: 10.2214/ajr.149.2.351

30. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. (2001) 32:1318–22. doi: 10.1161/01.STR.32.6.1318

31. Vilar-Bergua A, Riba-Llena I, Nafria C, Bustamante A, Llobart V, Delgado P, et al. Blood and CSF biomarkers in brain subcortical ischemic vascular disease: involved pathways and clinical applicability. J Cereb Blood Flow Metab. (2016) 36:55–71. doi: 10.1038/jcbfm.2015.68

32. Bridges LR, Andoh J, Lawrence AJ, Khoong CHL, Poon W, Esiri MM, et al. Blood-brain barrier dysfunction and cerebral small vessel disease (Arteriolosclerosis) in brains of older people. J Neuropathol Exp Neurol. (2014) 73:1026–33. doi: 10.1097/NEN.0000000000000124

33. Wardlaw JM, Makin S, Valdés Hernández MC, Armitage PA, Heye AK, Chappell F, et al. Blood-brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: evidence from a cohort study. Alzheimers Dement. (2017) 13:634–43. doi: 10.1016/j.jalz.2016.09.006

34. O’Brien JS, Sampson EL. Lipid composition of the normal human brain: gray matter, white matter, and myelin. J Lipid Res. (1965) 6:537–44.

35. Morell P, Quarles RH. Characteristic composition of myelin. In: Siegel GJ, Agrawal BW, Albers RW, Fisher SK, Uhler MD, editors. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th ed. Philadelphia, PA: Lippincott-Raven (1999). Available online at: https://www.ncbi.nlm.nih.gov/books/NBK28221/

36. Olsen AB, Færgeman NJ. Sphingolipids: membrane microdomains in brain development, function and neurological diseases. Open Biol. (2017) 7:170069. doi: 10.1098/rsob.170069

37. Imgrund S, Hartmann D, Farwanah H, Eckhardt M, Sandhoff R, Degen J, et al. Adult ceramide synthase 2 (CERS2)-deficient mice exhibit myelin sheath defects, cerebellar degeneration, and hepatocarcinomas. J Biol Chem. (2009) 284:33549–60. doi: 10.1074/jbc.M109.031971

38. Capodivento G, Visigalli D, Garnero M, Fancellu R, Ferrara MD, Basi A, et al. Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies. Sci Rep. (2017) 7:7831. doi: 10.1038/s41598-017-08314-1

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor declared a past co-authorship with author JH.

Copyright © 2019 Azizkhanian, Sheth, Iavarone, Lee, Kakarla and Hinman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.